



## Arbutus Presents HBV Data at Upcoming Scientific Conferences

September 22, 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.

### **Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA**

Presentations Include:

- RNA Interference: A New Tool in the Toolbox for Treatment of HBV *by Amy Lee, Senior Director, Research*
- HBV Capsid Assembly Inhibitors *by Rene Rijnbrand, Vice President, Head of Biology*

### **Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA**

Presentation Includes:

- RNAi Based Human Therapy for Chronic Hepatitis B Infection *by Amy Lee, Senior Director, Research*

These presentations will be available by visiting the Investor section of [www.arbutusbio.com](http://www.arbutusbio.com) and selecting Events and Presentations.

### **About Arbutus**

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### **Contact Information**

#### **Investors**

Adam Cutler

Senior Vice President, Corporate Affairs

Phone: 604-419-3200

Email: [acutler@arbutusbio.com](mailto:acutler@arbutusbio.com)

Tiffany Tolmie

Manager, Investor Relations

Phone: 604-419-3200

Email: [ttolmie@arbutusbio.com](mailto:ttolmie@arbutusbio.com)

#### **Media**

David Schull

Russo Partners

Phone: 858-717-2310

Email: [david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

 [Primary Logo](#)

Source: Arbutus Biopharma Corporation